Best Life Sciences Companies in Groningen, Netherlands
The 37 best Life Sciences companies in Groningen, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Mucosis.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Groningen
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Mucosis Mucosal vaccines for the prevention and treatment of infectious diseases (specifically against respiratory… | $15M | 127 mo ago | Series B | — | 2006 | — | 45 patents Thermally stable vaccine antigens and adjuvant formulations for RSV and other pathogens | — |
| 2 | Polyganics Bioresorbable medical devices for regenerative medicine | $7M | 76 mo ago | Acquired | — | 1999 | — | 121 patents Biomedical adhesive polymers and drug‑eluting foams for tissue repair and drug delivery | — |
| 3 | EV Biotech Developer of biological productions of biomaterials | $5M | 41 mo ago | Seed | Linda Dijkshoorn CEO and founder | 2018 | WordPressMySQLPHP+21 | — | — |
| 4 | QDI systems Developer of X-ray imaging diagnostic devices for medical applications | $5M | 18 mo ago | Series A | Artem Shulga Founder & CEO | 2018 | WordPressMySQLPHP+11 | 12 patents Colloidal Pb‑chalcogenide nanocrystals for SWIR/X‑ray detectors and printable conductive polymer inks for optoelectronic devices. | — |
| 5 | InnoCore Pharma Provider of pre-clinical drug delivery formulation services | $656K | 135 mo ago | Funding Raised | — | 2003 | WordPressMySQLPHP+18 | — | — |
| 6 | PolyVation Developer of polymers for biomedical and pharma applications | $265K | 129 mo ago | Funding Raised | Theo Flipsen Founder & CEO | 1996 | PHPApache HTTP ServerTypekit+7 | 14 patents Biodegradable poly(ortho ester) polymers and antimicrobial agents for medical/food applications | — |
| 7 | Sencilia Provider of IV infusion monitoring sensors to prevent accidental over or under dosage in vulnerable patients | — | 11 mo ago | Seed | Amar Kamat Founder & CEO | 2021 | — | 2 patents Micro-scale fluid flow measurement sensors for precise liquid/gas flow monitoring | 1 partnership |
| 8 | AGILeBiotics Developer of antibiotics for MDR infections using a proprietary platform technology | — | 97 mo ago | Seed | Andreas Bastian Co-Founder | 2017 | — | 5 patents Novel 3''-substituted aminoglycoside antibiotics enhancing antibacterial activity | — |
Top 8 Life Sciences companies in Groningen
#1
Series A · Groningen, Groningen · founded 2018 · 8 employees$4.7Mraised▾
Developer of X-ray imaging diagnostic devices for medical applications. The company has developed an X-ray detector based on Quantum Dot technology that is semiconductor nanoparticles. Its patented QD technology allows scalable fabrication of semiconductive QD films that can be used in SWIR image sensors, solar cells, NIR LEDs, thermal detectors, and more. It also helps in mammography detection based on quantum dots which provides resolution mammograms for doctors, and dose reduction for patients with lower costs for hospitals.
- Feb 2025Grant (prize money)$2.6M
- Jan 2024Series A$3.3M
- Jan 2024Conventional Debt$2.2M
- May 2022Seed$1.4M
#2
Seed · Groningen, Groningen · founded 2018 · 30 employees$4.8Mraised▾
EV Biotech is developing the biological production of biomaterials. The company is developing the chemical compounds for Flavors & Fragrances, Biomaterials, Agriculture and Pharmaceutical markets using microbiology, genetic engineering, and system biology among others.
- Mar 2023Seed$4.8M
- Oct 2020Grant (prize money)$130.6K
#3
Series B · Groningen, Groningen · founded 2006 · 16 employees$14.5Mraised▾
Mucosis is developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Its lead product candidate is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus (RSV) infection. It has influenza vaccine candidate in clinical development which can be administered intranasally. Also have research programmes aimed at developing vaccines to prevent; pneumococcal related diseases and bacterial diarrhoea.
- Jan 2016Grant (prize money)$4M
- Jan 2015Series B$3.5M
- May 2014Conventional Debt$6.8M
- Apr 2014Series B$6.9M
#4
Acquired · Groningen, Groningen · founded 1999 · 75 employees$7Mraised▾
Polyganics is a medical technology company developing bioresorbable medical devices that facilitate natural tissue repair and regeneration based on their proprietary polymer technology. The company's platform allows the integration of polymer chemistry and engineering design to enable development of medical products with specific features such as porous scaffolds, tubes, sheets, sleeves or foams with tailor-made properties. The company's current product range covers ENT products, peripheral nerve repair and neurosurgery products and general surgery products. In 2014, Polyganics divested its ENT portfolio to Stryker.
- May 2020Grant (prize money)$1.3M
- Apr 2019Grant (prize money)$4.3M
- Dec 2017Grant (prize money)$1.4M
#5
Funding Raised · Groningen, Groningen · founded 2003 · 36 employees$656Kraised▾
InnoCore Pharma is a Dutch, pre-clinical stage, drug formulation company. It makes drug-eluting devices (stents) and drug delivery formulations (microspheres, implants, PEG-stabilized controlled release protein therapeutics). In microsphere drug delivery, it is developing therapeutics for cancer, growth factor, intra-ocular, and osteoarthritis. In implants, it is developing therapeutics for cancer and intraocular diseases. It also offers its drug delivery formulation services to its clients.
- Jun 2015Grant (prize money)$656K
#6
Funding Raised · Groningen, Groningen · founded 1996 · 50 employees$265.2Kraised▾
PolyVation (formerly Polymer Service Centre), a spin-off from the Polymer Laboratories of the University of Groningen, is engaged in the research, development, and manufacturing of polymers for biomedical and pharma applications. The company has capabilities for contract commercial manufacturing of specialty polymers, monomers, additives or polymer-based formulations as per EU and FDA cGMP guidelines. The company claims to have expertise in the synthesis of bioabsorbable and biostable polymers and offers manufacturing services for polymers which can be used for injectable drug delivery, ophthalmic and cardiovascular devices, tissue engineering products, phase transfer gels, and diagnostic membranes.
- Dec 2015Grant (prize money)$265.2K
#7
Seed · Groningen, Groningen · founded 2021 · 6 employees—raised▾
Provider of IV infusion monitoring sensors to prevent accidental over or under dosage in vulnerable patients. It offers Rely-V an IV infusion monitoring technology for patients in NICUs and PICUs that integrates drug flow readings, continuously monitors, alert nurses to discrepancies, eliminates IV flow-related medication errors in neonatal and paediatric intensive care.
- Sep 2025Seed—
#8
Seed · Groningen, Groningen · founded 2017 · 3 employees—raised▾
AGILeBiotics is developing antibiotics for MDR infections using a proprietary platform technology. The company is a spin-off from the University of Groningen. The company has developed a proprietary technology called OxaSelect that converts existing antibiotics. Using OxaSelect, the company seeks to produce a library of antibiotic candidates based on structurally complex natural products. OxaSelect allows site-selective modification giving access to modified antibiotics, which overcome bacterial resistance mechanism.
- Jul 2018Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Groningen researches in biotechnology
- University of Groningen19
- University Medical Center Groningen15
- Dialyse Centrum Groningen1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.